Clinical Trials Logo

Clinical Trial Summary

The purpose is to see how X-linked adrenoleukodystrophy (X-ALD) is associated with strength and sensation using MRI, in women with X-ALD. The investigators will also see whether exercise can improve these symptoms for women with X-ALD.


Clinical Trial Description

X-linked adrenoleukodystrophy (X-ALD), a [sex-linked] progressive neurodegenerative disease, is caused by a defect in the ABCD1 gene. The disease is expressed in multiple ways, but the most common adult form is adrenomyeloneuropathy (AMN), which results in slowly progressive changes in muscle tone and weakness, sensory loss, and dysfunction of the autonomic nervous system. In a previous study the investigators linked abnormalities in the [brain/spinal cord] to lower extremity weakness in men with AMN; however, there have been no studies evaluating these relationships in women carriers (i.e., women with AMN). It is unknown, in women with AMN, how the pattern of damage in the brain and spinal cord relates to disability and if these patterns predict responsiveness to treatment. The investigators hypothesize that by using magnetization transfer (MT) and diffusion tensor imaging (DTI), two magnetic resonance imaging (MRI) modalities, to track particular changes in the brain and spinal cord will predict disability and additionally, who is likely to respond best to a training regimen. The investigators expect that these more advanced imaging techniques will be more sensitive and accurate quantitative measures of clinical motor function and women with greater loss in the spinal cord compared to the brain will benefit most from training to improve disability. To test this hypothesis, women with AMN will receive MRI scans at baseline and complete measures of global walking and lower extremity impairments of vibration sensation, spasticity, and strength at three time-points: baseline, 12 weeks, and 18 weeks after baseline. The group will participate in a resistive training program for 12 weeks. MRI data will be correlated to changes over time in measures of impairment to determine their relationships. The linking of this information will not only be important for better defining disability in women with AMN but it will also help to guide physicians and rehabilitation therapists in predicting who is likely to respond to rehabilitative interventions, as well as for optimizing the effects of future pharmacological interventions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01594853
Study type Interventional
Source Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Contact
Status Completed
Phase N/A
Start date May 2012
Completion date October 2014

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05911919 - Validation of a Prognostic Biomarker Using Brain Diffusion MRI in X-linked Adrenoleukodystrophy
Recruiting NCT03727555 - Lentiviral Gene Therapy for X-ALD N/A
Completed NCT02595489 - A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Phase 1
Completed NCT04687007 - SMART-ALD - A New Lifestyle Intervention to Improve Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD) N/A
Completed NCT01165060 - The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) N/A
Recruiting NCT05939232 - Registry of X-linked Adrenoleukodystrophy
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Completed NCT03864523 - Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy Phase 2
Recruiting NCT06178120 - Disease Progression in Women With X-linked Adrenoleukodystrophy
Recruiting NCT03278899 - A Study to Prospectively Assess Disease Progression in Male Children With X-ALD
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Recruiting NCT04675749 - Quality of Life in Women With X-linked Adrenoleukodystrophy
Withdrawn NCT03196765 - Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Phase 1/Phase 2
Withdrawn NCT01787578 - Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Phase 1
No longer available NCT02233257 - Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy N/A